Semglee® (insulin glargine-yfgn) – First new interchangeable biosimilar approval
July 28, 2021 - The FDA announced the approval of Viatris and Biocon Biologics’ Semglee (insulin glargine-yfgn), an interchangeable biosimilar to Sanofi’s Lantus® (insulin glargine).
Download PDF
